TXG 📈 10X Genomics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US88025U1097
TXG: Instruments, Consumables, Software, Microfluidic Chips, Reagents, Slides
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. Web URL: https://www.10xgenomics.com
Additional Sources for TXG Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TXG Stock Overview
Market Cap in USD | 1,850m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2019-09-12 |
TXG Stock Ratings
Growth 5y | -92.4% |
Fundamental | -20.3% |
Dividend | - |
Rel. Strength Industry | -3366 |
Analysts | 3.76/5 |
Fair Price Momentum | 8.45 USD |
Fair Price DCF | 4.96 USD |
TXG Dividends
No Dividends PaidTXG Growth Ratios
Growth Correlation 3m | -63.7% |
Growth Correlation 12m | -91.6% |
Growth Correlation 5y | -78.7% |
CAGR 5y | -29.25% |
CAGR/Mean DD 5y | -0.55 |
Sharpe Ratio 12m | -1.88 |
Alpha | -111.65 |
Beta | 1.49 |
Volatility | 76.17% |
Current Volume | 2024.7k |
Average Volume 20d | 2013.3k |
What is the price of TXG stocks?
As of December 21, 2024, the stock is trading at USD 14.04 with a total of 2,024,726 shares traded.
Over the past week, the price has changed by -8.96%, over one month by +0.29%, over three months by -42.04% and over the past year by -76.15%.
As of December 21, 2024, the stock is trading at USD 14.04 with a total of 2,024,726 shares traded.
Over the past week, the price has changed by -8.96%, over one month by +0.29%, over three months by -42.04% and over the past year by -76.15%.
Is 10X Genomics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, 10X Genomics is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -20.28 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TXG as of December 2024 is 8.45. This means that TXG is currently overvalued and has a potential downside of -39.81%.
Neither. Based on ValueRay Fundamental Analyses, 10X Genomics is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -20.28 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TXG as of December 2024 is 8.45. This means that TXG is currently overvalued and has a potential downside of -39.81%.
Is TXG a buy, sell or hold?
10X Genomics has received a consensus analysts rating of 3.76. Therefor, it is recommend to hold TXG.
10X Genomics has received a consensus analysts rating of 3.76. Therefor, it is recommend to hold TXG.
- Strong Buy: 6
- Buy: 2
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecast for TXG stock price target?
According to ValueRays Forecast Model, TXG 10X Genomics will be worth about 9.5 in December 2025. The stock is currently trading at 14.04. This means that the stock has a potential downside of -32.34%.
According to ValueRays Forecast Model, TXG 10X Genomics will be worth about 9.5 in December 2025. The stock is currently trading at 14.04. This means that the stock has a potential downside of -32.34%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 20.3 | 44.5% |
Analysts Target Price | 60.3 | 329.7% |
ValueRay Target Price | 9.5 | -32.3% |